uric acid has been researched along with Hyperlipoproteinemia Type II in 9 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atorvastatin is a powerful and safe lipid-modifying agent for LDL cholesterol; it also modifies HDL cholesterol and triglyceride concentrations, and may suffice as a single agent for many subjects with heterozygous FH." | 2.68 | Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. ( Bateman, ME; Byrnes, P; Firth, JC; Marais, AD; Martens, C; Mountney, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (66.67) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rać, ME | 1 |
| Safranow, K | 1 |
| Garanty-Bogacka, B | 1 |
| Dziedziejko, V | 1 |
| Kurzawski, G | 1 |
| Goschorska, M | 1 |
| Kuligowska, A | 1 |
| Pauli, N | 1 |
| Chlubek, D | 1 |
| HARRIS-JONES, JN | 1 |
| Kaffarnik, H | 1 |
| Schneider, J | 1 |
| Schubotz, R | 1 |
| Zöfel, P | 1 |
| Hausmann, L | 1 |
| Goebel, KM | 1 |
| Sirtori, M | 1 |
| Montanari, G | 1 |
| Gianfranceschi, G | 1 |
| Malacrida, MG | 1 |
| Battistin, P | 1 |
| Morazzoni, G | 1 |
| Tremoli, E | 1 |
| Colli, S | 1 |
| Maderna, P | 1 |
| Sirtori, CR | 1 |
| Zoppini, A | 1 |
| Teodori, S | 1 |
| Taccari, E | 1 |
| Schwartzkopff, W | 1 |
| Schilling, A | 1 |
| Calder, D | 1 |
| Ducobu, J | 1 |
| Marais, AD | 1 |
| Firth, JC | 1 |
| Bateman, ME | 1 |
| Byrnes, P | 1 |
| Martens, C | 1 |
| Mountney, J | 1 |
| Wittenstein, B | 1 |
| Klein, M | 1 |
| Finckh, B | 1 |
| Ullrich, K | 1 |
| Kohlschütter, A | 1 |
2 trials available for uric acid and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Clofibrate; Fatty Alcohols; Female; Humans; Hy | 1983 |
Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HD | 1997 |
7 other studies available for uric acid and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
CD36 gene polymorphism and plasma sCD36 as the risk factor in higher cholesterolemia.
Topics: Adolescent; Apolipoprotein A-I; Blood Pressure; Body Mass Index; CD36 Antigens; Child; Cholesterol, | 2018 |
Hyperuricaemia and essential hypercholesterolaemia.
Topics: Cholesterol; Humans; Hyperlipoproteinemia Type II; Hyperuricemia; Lipidoses; Uric Acid | 1957 |
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
[Value of synovial biopsy in the diagnosis of arthropathies associated with hyperlipoproteinemias].
Topics: Arthritis; Biopsy, Needle; Humans; Hyperlipoproteinemia Type II; Knee Joint; Synovial Membrane; Uric | 1980 |
[Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
Topics: Blood Glucose; Cholesterol; Clofibrate; Creatinine; Delayed-Action Preparations; Humans; Hyperlipopr | 1980 |
[Clinical study of fenofibrate in hyperlipoproteinemias].
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoprotei | 1980 |
Plasma antioxidants in pediatric patients with glycogen storage disease, diabetes mellitus, and hypercholesterolemia.
Topics: Adolescent; Adult; Antioxidants; Ascorbic Acid; Child; Child, Preschool; Cholesterol; Chromatography | 2002 |